2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 15:09, 10 December 2023
, 10 December 2023→Clinical Trials
| Line 332: | Line 332: | ||
|- | |- | ||
|{{pmid_text|35182418}} | |{{pmid_text|35182418}} | ||
|[[RCT]], | |[[RCT]], 2 weeks | ||
*1g MIB-626 once daily | *1g MIB-626 once daily | ||
*1g MIB-626 twice daily | *1g MIB-626 twice daily | ||
| Line 348: | Line 348: | ||
|- | |- | ||
|{{pmid_text|36740954}} | |{{pmid_text|36740954}} | ||
|[[RCT]], | |[[RCT]], 4 weeks | ||
*500mg MIB-626 twice daily | *500mg MIB-626 twice daily | ||
*placebo | *placebo | ||
| Line 363: | Line 363: | ||
|- | |- | ||
|{{pmid text|36797393}} | |{{pmid text|36797393}} | ||
|[[RCT]], 12 weeks, capsules | |||
* placebo (n=17) | |||
* 2x125 mg/day (n=17) | |||
| | | | ||
* 34 healthy male and female | |||
* age 40-59 | |||
| | | | ||
* 250 mg of NMN for 12 weeks does not significantly reduce artery stiffness — a risk factor for cardiovascular disease, dementia, and death — in healthy middle-aged adults. | * 250 mg of NMN for 12 weeks does not significantly reduce artery stiffness — a risk factor for cardiovascular disease, dementia, and death — in healthy middle-aged adults. | ||